BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25712343)

  • 1. Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.
    Nunes M; Vrignaud P; Vacher S; Richon S; Lièvre A; Cacheux W; Weiswald LB; Massonnet G; Chateau-Joubert S; Nicolas A; Dib C; Zhang W; Watters J; Bergstrom D; Roman-Roman S; Bièche I; Dangles-Marie V
    Cancer Res; 2015 Apr; 75(8):1560-6. PubMed ID: 25712343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
    Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
    Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors.
    Cho YB; Hong HK; Choi YL; Oh E; Joo KM; Jin J; Nam DH; Ko YH; Lee WY
    J Surg Res; 2014 Apr; 187(2):502-9. PubMed ID: 24332554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
    Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L
    Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis.
    Wang J; Xing B; Liu W; Li J; Wang X; Li J; Yang J; Ji C; Li Z; Dong B; Gao J; Shen L
    Theranostics; 2019; 9(12):3485-3500. PubMed ID: 31281492
    [No Abstract]   [Full Text] [Related]  

  • 6. Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.
    Colombo PE; du Manoir S; Orsett B; Bras-Gonçalves R; Lambros MB; MacKay A; Nguyen TT; Boissière F; Pourquier D; Bibeau F; Reis-Filho JS; Theillet C
    Oncotarget; 2015 Sep; 6(29):28327-40. PubMed ID: 26334103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
    Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
    Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
    Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps.
    Ilie M; Nunes M; Blot L; Hofman V; Long-Mira E; Butori C; Selva E; Merino-Trigo A; Vénissac N; Mouroux J; Vrignaud P; Hofman P
    Cancer Med; 2015 Feb; 4(2):201-11. PubMed ID: 25470237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.
    Kanaya N; Somlo G; Wu J; Frankel P; Kai M; Liu X; Wu SV; Nguyen D; Chan N; Hsieh MY; Kirschenbaum M; Kruper L; Vito C; Badie B; Yim JH; Yuan Y; Hurria A; Peiguo C; Mortimer J; Chen S
    J Steroid Biochem Mol Biol; 2017 Jun; 170():65-74. PubMed ID: 27154416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
    Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
    Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
    Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
    Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.
    Galimi F; Torti D; Sassi F; Isella C; Corà D; Gastaldi S; Ribero D; Muratore A; Massucco P; Siatis D; Paraluppi G; Gonella F; Maione F; Pisacane A; David E; Torchio B; Risio M; Salizzoni M; Capussotti L; Perera T; Medico E; Di Renzo MF; Comoglio PM; Trusolino L; Bertotti A
    Clin Cancer Res; 2011 May; 17(10):3146-56. PubMed ID: 21447729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling rectal cancer to advance neoadjuvant precision therapy.
    Janakiraman H; Zhu Y; Becker SA; Wang C; Cross A; Curl E; Lewin D; Hoffman BJ; Warren GW; Hill EG; Timmers C; Findlay VJ; Camp ER
    Int J Cancer; 2020 Sep; 147(5):1405-1418. PubMed ID: 31989583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
    Gao H; Korn JM; Ferretti S; Monahan JE; Wang Y; Singh M; Zhang C; Schnell C; Yang G; Zhang Y; Balbin OA; Barbe S; Cai H; Casey F; Chatterjee S; Chiang DY; Chuai S; Cogan SM; Collins SD; Dammassa E; Ebel N; Embry M; Green J; Kauffmann A; Kowal C; Leary RJ; Lehar J; Liang Y; Loo A; Lorenzana E; Robert McDonald E; McLaughlin ME; Merkin J; Meyer R; Naylor TL; Patawaran M; Reddy A; Röelli C; Ruddy DA; Salangsang F; Santacroce F; Singh AP; Tang Y; Tinetto W; Tobler S; Velazquez R; Venkatesan K; Von Arx F; Wang HQ; Wang Z; Wiesmann M; Wyss D; Xu F; Bitter H; Atadja P; Lees E; Hofmann F; Li E; Keen N; Cozens R; Jensen MR; Pryer NK; Williams JA; Sellers WR
    Nat Med; 2015 Nov; 21(11):1318-25. PubMed ID: 26479923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer.
    Isella C; Brundu F; Bellomo SE; Galimi F; Zanella E; Porporato R; Petti C; Fiori A; Orzan F; Senetta R; Boccaccio C; Ficarra E; Marchionni L; Trusolino L; Medico E; Bertotti A
    Nat Commun; 2017 May; 8():15107. PubMed ID: 28561063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived xenograft models of breast cancer and their predictive power.
    Whittle JR; Lewis MT; Lindeman GJ; Visvader JE
    Breast Cancer Res; 2015 Feb; 17(1):17. PubMed ID: 25849559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling of Patient-Derived Xenografts in Colorectal Cancer.
    Katsiampoura A; Raghav K; Jiang ZQ; Menter DG; Varkaris A; Morelli MP; Manuel S; Wu J; Sorokin AV; Rizi BS; Bristow C; Tian F; Airhart S; Cheng M; Broom BM; Morris J; Overman MJ; Powis G; Kopetz S
    Mol Cancer Ther; 2017 Jul; 16(7):1435-1442. PubMed ID: 28468778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers.
    Nosho K; Yamamoto H; Takahashi T; Mikami M; Taniguchi H; Miyamoto N; Adachi Y; Arimura Y; Itoh F; Imai K; Shinomura Y
    Carcinogenesis; 2007 Jun; 28(6):1364-70. PubMed ID: 17183069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
    Pan CX; Zhang H; Tepper CG; Lin TY; Davis RR; Keck J; Ghosh PM; Gill P; Airhart S; Bult C; Gandara DR; Liu E; de Vere White RW
    PLoS One; 2015; 10(8):e0134346. PubMed ID: 26270481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.